Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients

1

Hematopoietic cell transplant recipients are at increased risk for severe COVID-19 outcomes compared to other cancer patients.
2

The study evaluated the humoral response to SARS-CoV-2 vaccines in HCT recipients, focusing on anti-S RBD and neutralizing antibodies.
3

A total of 126 patients were enrolled, with 79% receiving allogeneic and 21% autologous transplants, median age being 59.5 years.
4

Significant increases in anti-S RBD titers and neutralization percentages were observed after the second and third vaccine doses.
5

Younger age, autologous transplants, and longer time from transplant to vaccination were associated with higher antibody responses.

Bone Marrow Transplantation

by Qamar J. Khan, Cory R. Bivona, Ben Liu, Maggie Nelson, Grace A. Martin, Muhammad Umair Mushtaq, Priyanka Sharma, Natalie R. Streeter, Marc Hoffmann, Gary C. Doolittle, Cuncong Zhong, Laura Mitchell, Kevin H. Li, Ziyan Y. Pessetto, Arnab Ghosh, Harsh B. Pathak, Jun Zhang, Andrew K. Godwin, Joseph P. McGuirk
April 6, 2022

1